To include your compound in the COVID-19 Resource Center, submit it here.

Tarceva erlotinib: Additional Phase II data

Researchers at the M.D. Anderson Cancer Center reported additional data from a subgroup of 101 stage IV NSCLC patients who had gene expression profiles obtained from pretreatment core needle biopsies in the adaptive, open-label, U.S. Phase II BATTLE trial showing that 2 gene signatures were predictive of disease control with Tarceva in

Read the full 520 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE